Press Room

Article / Nov 18, 2016

A True Diversifier

Macau Business, November 18, 2016

Last Sunday, I had the opportunity to attend the St. Martens party (in Portuguese ‘Magusto’) at the Hovione premises in Taipa. For those who do not know Hovione, it is a corporation with a manufacturing plant in Macau and premises in eight other locations, from Lisbon to New Jersey, and in Mainland China, India, Japan, Hong Kong, and Ireland. Driven by the vision of its CEO, Mr. Guy Villax, it has expanded hugely over the last two decades.

It is also the reason why you read this column here in Macau. As a matter of fact, in early 2012 I was placed in Macau by the then ICEP (Portuguese external trade agency) now AICEP.

Truth be told, it is one of the sole examples of diversification of the economy in Macau.

 

Read the entire article at Macau Business

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025